-
- Posted Monday May 2, 2022
TGen-led study suggests a drug combination that might prove effective for 1 in 3 glioblastoma patients
MLN4924 is associated with a ‘signature of vulnerability,’ providing a precision-medicine guide for planned nationwide clinical trials
PHOENIX, Ariz. — May 2, 2022 — Based on the findings of a new study led by the Translational Genomics Research Institute (TGen), part of City of Hope, a coast-to-coast clinical trial is planned that, if successful, could lead to FDA approval of the first new drug treatment in more than a decade for glioblastoma, the most common and aggressive type of brain cancer.
Using precision medicine to select only participants with a specific genomic “signature of vulnerability,” researchers expect the new treatment could help up to a third of all glioblastoma patients. An estimated 18,000 Americans are expected to die this year from brain cancer, the nation’s seventh leading cause of cancer death.
Results of a preclinical study published in Neuro-Oncology suggest that a drug combination of MLN4924, also known as Pevonedistat, when given in combination with a second drug called Etoposide, could help glioblastoma patients whose cancer cells have lost PTEN, a tumor-suppressor gene.
Genomic sequencing of patient-derived tissue samples showed those samples with a loss of PTEN also showed a spike in the expression of a gene called TOP2A, which research suggests resists the effectiveness of MLN4924. By using Etoposide to block TOP2A, researchers believe glioma cells will be weakened enough for MLN4924 to kill the cancer.
“I’m greatly encouraged,” said Michael Berens, Ph.D., head of TGen’s Glioma Research Lab, and one of the study’s senior authors. “There hasn’t been a new drug approved for glioblastoma in 13 years. Knowing the right patients to enroll in the clinical trial, through study of molecular features of sensitive and resistant tumors, and only treating patients whose tumors have the signature of vulnerability, should set us on a path to a new approved drug treatment.”
The last drug to receive FDA approval for glioblastoma was Avastin in 2009. The average patient survival for glioblastoma remains stuck at about 15-18 months.
Drug combination 10 years in the making
The identification of MLN4924/Pevonedistat grew out of a high-throughput screen nearly a decade ago of more than 100,000 different drugs, trying to find an effective molecule that also was small enough to pass through the protective web of extra-small capillaries that surrounds the brain, forming what is known as the blood-brain barrier.
From those initial screenings, researchers identified four drugs — Arsenic Trioxide, Methoxyamine, Selinexor and MLN4924/Pevonedistat. The first three drugs have already undergone clinical trials for glioblastoma patients, but were considered failures because they didn’t substantially extend the survival of a sufficient number of patients. However, Dr. Berens noted that they did work for a small percentage of patients with particular genomic profiles. Pevonedistat, which was originally developed for another disease, has never been tested in patients with glioblastoma.
Dr. Berens and his team are planning a series of clinical trials at sites across the nation that will test the safety and effectiveness of MLN4924/Pevonedistat with Etoposide. That drug combination, along with at least three others, will be tested in the Glioblastoma Umbrella Signature Trial (GUST). An abstract of the project was presented April 13 at the annual meeting of the American Association for Cancer Research (AACR) in New Orleans.
“Our use of multiple vulnerability signatures in the GUST trial will demonstrate how a precision-medicine model can support an efficient clinical trial for diseases, such as glioblastoma, that are characterized by multiple mutations that result in multiple tumor types,” said Associate Professor Patrick Pirrotte, Ph.D., Director of TGen’s Collaborative Center for Translational Mass Spectrometry, and one of the study’s authors.
"This study leveraged state-of-the-art genomic technologies — transcriptomics (RNA) and proteomics — to identify how the loss of the tumor suppressor PTEN affects glioblastoma cells treated with MLN4924,” said Dr. Pirrotte. “Proteomics was key to discovering the increase in the protein expressed by TOP2A, which led to the recommended use of Etoposide in conjunction with MLN4924."
Also contributing to this study were: University of California San Diego, and the San Diego branch of Ludwig Cancer Research.
Funding for the preclinical study — PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors — was provided by the National Institutes of Health; and by Defeat GBM Research Collaborative, a subsidiary of the National Brain Tumor Society.
# # #
About TGen, part of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is part of City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: CityofHope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen.
Media Contact:
Galen Perry
Marketing and Communication
602-343-8423
[email protected]
